Excellent trade so far on RIGL. The company reported earnings and everything was in line. They have data upcoming in April and an April 17thFDA approval date. Fantastic! I hopped in after an initial market selloff and the stock trudged higher all day long.
I about three-fourths of the for about $2,500 in just a few hours and am keeping the other half for higher. This also gives me some room to add back the 2,500 shares on a dip, if it happens.
Perfect trading!
I also continue to hold CDTX, which is performing well so far.
I’m going to take SVRA off the watch list today. The company announced that they will have an earnings call right after their catalyst date. That makes the potential run up even more difficult.
I’m also taking EDAP off the watch list for now as well. The company is set to have earnings in early April, and there I expect some more clarity on their catalyst. For now, it’s been a tough one to track on low volume.
[Ed.note: Kyle Dennis runs BiotechBreakouts.com. He is an event-based trader, who prefers low-priced and small-cap biotech stocks.
To replace those names, I have 4 new names to the list to add here below as well!
Just a reminder, charts and targets are updated every Monday morning!
New Catalyst Swing names (1 – 4 week holds) I am watching…
AVEO Pharmaceuticals (AVEO)
Catalyst Dates: Phase 3 data due out in the second quarter
Buy Zone: $2.80 to $3.00
Profit Zone: $3.50 or higher
Stop Zone: $2.60 or below
Celldex Therapeutics (CLDX)
Catalyst Dates: Phase 2b data due out in second quarter
Buy Zone: $2.40 to $2.55
Profit Zone: $2.80 or higher
Stop Zone: $2.20 or below
Pluristem (PSTI)
Catalyst Dates: Phase 2 data due out in the second quarter
Buy Zone: $1.35 to $1.45
Profit Zone: $1.75 or higher
Stop Zone: $1.20 or below
Kitov Pharma (KTOV)
Catalyst Dates: FDA Approval date of May 31
Buy Zone: $2.60 to $2.80
Profit Zone: $3.25 or higher
Stop Zone: $2.20 or below
Catalyst Swing names (1 – 4 week holds) I am watching…
TherapeuticsMD (TXMD)
Catalyst Dates: FDA approval date of May 29th
Buy Zone: $4.90 to $5.20
Profit Zone: $6.00 or higher
Stop Zone: $4.60 or below
Edge Therapeutics (EDGE)
Catalyst Dates: Phase 3 interim data due out in April
Buy Zone: $15.20 to $15.50
Profit Zone: $16.50 or higher
Stop Zone: $15.00 or below
Medicinova (MNOV)
Catalyst Dates: Phase 1b/2a abstract to be presented April 27th
Buy Zone: $10.50 to $11.00
Profit Zone: $12.00 or higher
Stop Zone: $10.15 or below
Selecta Biosciences (SELB)
Catalyst Dates: Phase 2 data in early April
Buy Zone: $8.50 to $9.50
Profit Zone: $11.50 or higher
Stop Zone: $8.00 or below
Viking Therapeutics (VKTX)
Catalyst Dates: Phase 2 data for fatty liver disease due out in the 2nd quarter.
Buy Zone: $6.00 to $6.50
Profit Zone: $7.50 or higher
Stop Zone: $5.50 or below
Seattle Genetics (SGEN)
Catalyst Dates: FDA approval date of May 1
Buy Zone: $53.00 to $56.00
Profit Zone: $60.00 or higher
Stop Zone: $51.50 or below
Dova Pharmaceuticals (DOVA)
Catalyst Dates: FDA approval date of May 21
Buy Zone: $30.00 to $32.00
Profit Zone: $36.00 or higher
Stop Zone: $29.50 or below
Rigel Pharmaceuticals (RIGL)
Catalyst Dates: FDA approval date of April 17th for immune thrombocytopenic purpura
Buy Zone: $3.50 to $3.90
Profit Zone: $4.50 or higher
Stop Zone: $3.40 or below
Clovis Oncology (CLVS)
Catalyst Dates: FDA approval date of April 6th for ovarian cancer
Buy Zone: $52.00 to $55.00
Profit Zone: $60.00 or higher
Stop Zone: $49.00 or below
Ultragenyx Pharmaceuticals (RARE)
Catalyst Dates: FDA approval date of April 17th for X-linked Hypophosphatemia
Buy Zone: $44.00 to $47.00
Profit Zone: $55.00 or higher
Stop Zone: $41.00 or below
Progenics (PGNX)
Catalyst Dates: FDA Approval date of April 30th
Buy Zone: $5.75 to $6.20
Profit Zone: $7.00 or higher
Stop Zone: $5.10 or below
CorMedix (CRMD)
Catalyst Dates: Phase 3 interim analysis due out in the second quarter. Likely a buy after their earnings call in March.
Buy Zone: $.30 to $.40
Profit Zone: $.60 or higher
Stop Zone: $.25 or below
Nabriva Therapeutics (NBRV)
Catalyst Dates: Phase 3 antibiotic data due out “spring 2018”
Buy Zone: $5.50 to $6.00
Profit Zone: $8.00 or higher
Stop Zone: $5.20 or below
Cidara Therapeutics (CDTX)
Catalyst Dates: Phase 2 Candidemia data due in the 1Q (likely sometime in March)
Buy Zone: $6.50 to $7.00
Profit Zone: $8.00 or higher
Stop Zone: $5.75 or below
Sophiris Bio (SPHS)
Catalyst Dates: Phase 2b initial biopsy data due late First Quarter.
Buy Zone: $1.95 to $2.15
Profit Zone: $2.40 or higher
Stop Zone: $1.75 or below
